logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
T

Talat Bessissow

mcgill university
H指数:34
被引数:4,432

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effectiveness and Safety of Advanced Combination Treatment in Patients With Refractory Inflammatory Bowel Disease or Concomitant Immune-Mediated Disease or Extraintestinal Manifestations: A Multicenter Canadian Study

难治性炎症性肠病或合并免疫介导性疾病或肠外表现的患者的先进联合治疗的有效性和安全性：一项多中心加拿大研究

American Journal of Gastroenterology
IF7.6
2026-02-013
PRE
Solitano, Virginia; Ogunsakin, Ropo Ebenezer; Yuan, Yuhong; Bernstein, Charles N.; Bessissow, Talat; Bressler, Brian; Hoentjen, Frank; Van Lierop, Lisa; Leung, Yvette; Ma, Christopher; Marshall, John Kenneth; Narula, Neeraj; Alahmari, Mohammed; Mccurdy, Jeffrey D.; Murthy, Sanjay; Panaccione, Remo; Rosenfeld, Greg; Milgrom, Raquel; Silverberg, Mark; Jairath, Vipul
Mirikizumab demonstrated high treatment persistence and effectiveness in a real-world retrospective study in Canadian adult patients with moderately to severely active Ulcerative Colitis

美立克珠单抗在加拿大中重度活动性溃疡性结肠炎成人患者真实世界回顾性研究中显示出高治疗持续性和有效性

Journal of Crohns & Colitis
IF8.7
2026-01-010
PRE
Jairath, V; Panaccione, R.; Bessissow, T.; Bressler, B.; Ng, G.; Glass, J.; Braun, M.; Movsessian, T.; Feagan, B. G.
Communicating Needs and Features of IBD Experiences study: Canadian individuals and healthcare professional perceptions of the experience and impact of symptoms of moderate-to-severe ulcerative colitis and Crohn's disease

关于IBD体验研究中的需求与特征沟通：加拿大个体和医疗保健专业人员对中重度溃疡性结肠炎和克罗恩病症状体验及影响的看法

Journal of the Canadian Association of Gastroenterology
IF2.7
2026-01-010
PRE
Jairath, Vipul; Bessissow, Talat; Glass, Jennifer; Braun, Marta; Gibble, Theresa Hunter; Movsessian, Taline; Atkinson, Christian; Ellis, Hilary; Dewar, Thomas; Panaccione, Remo
Fecal microbiota transplantation to reduce immune activation in ART-treated people with HIV with low CD4/CD8 ratio: protocol for the single-blind, randomized, placebo-controlled Gutsy study (CIHR/CTN PT038)

粪菌移植以降低接受抗逆转录病毒治疗且CD4/CD8比率低的人类免疫缺陷病毒感染者免疫激活：Gutsy研究（CIHR/CTN PT038）单盲、随机、安慰剂对照试验方案

TRIALS
IF2
2025-12-130
PRE
Isnard, Stephane; Berini, Carolina A.; Parvathy, Seema Nair; Feng, Hansen; Aiyana, Orthy; Royston, Lena; Mabanga, Tsoarello; Lakatos, Peter L.; Bessissow, Talat; Klein, Marina B.; Lebouche, Bertrand; Costiniuk, Cecilia T.; Routy, Bertrand; Silverman, Michael S.; Routy, Jean-Pierre
Upadacitinib is associated with better clinical and biochemical outcomes than tofacitinib in refractory, moderate-to-severe UC

乌帕替尼（Upadacitinib）与托法替尼（tofacitinib）相比，在难治性中重度溃疡性结肠炎（UC）中表现出更优的临床和生化结局。

Clinical Gastroenterology and Hepatology
IF12
2025-09-090
PRE
Bernadett Farkas; Tamás Resál; Peter L. Lakatos; Talat Bessissow; Jimmy K. Limdi; Alessandro Armuzzi; Cristina Bezzio; Edoardo V. Savarino; Simone Saibeni; George Michalopoulos; Mohamed Attauabi; Jakob Benedict Seidelin; Fotios S. Fousekis; Kostas Katsanos; Péter Bacsur; Anita Bálint; Emese Ivány; Zoltán Szepes; Klaudia Farkas; Tamás Molnár
Defining Fecal Calprotectin Cutoffs That Predict Endoscopic and Histologic Remission in Patients With Ulcerative Colitis

Drügg Hahn, G.; Lakatos, P.L.; Maedler-Kron, C.; Marcus, V.; Afif, W.; Wild, G.; Bitton, A.; Flores, C.; Francesconi, C.F.d.M.; Bessissow, T. 定义可预测溃疡性结肠炎患者内镜和组织学缓解的粪钙卫蛋白截断值。Inflamm. Bowel Dis. 2025, 31, 2977–2985. [Google Scholar] [CrossRef]

INFLAMMATORY BOWEL DISEASES
IF4.3
2025-09-010
PRE
Drugg Hahn, Gustavo; Lakatos, Peter Laszlo; Maedler-Kron, Chelsea; Marcus, Victoria; Afif, Waqqas; Wild, Gary; Bitton, Alain; Flores, Cristina; de Magalhaes Francesconi, Carlos Fernando; Bessissow, Talat

研究方向

暂未获取到该数据
P
Péter L. Lakatos
H 指数:86论文数:1,143被引数:3.3万
W
Waqqas Afif
H 指数:35论文数:293被引数:4,743
A
Alain Bitton
H 指数:68论文数:445被引数:2.7万
G
Gary Wild
H 指数:39论文数:240被引数:1.0万
E
Ernest G. Seidman
H 指数:72论文数:563被引数:1.8万
L
Lóránt Gönczi
H 指数:19论文数:136被引数:1,351
U
Uri Kopylov
H 指数:67论文数:550被引数:2.0万
P
Panu Wetwittayakhlang
H 指数:15论文数:85被引数:521
C
Christine Verdon
H 指数:11论文数:43被引数:610
J
Jason Reinglas
H 指数:12论文数:44被引数:548